-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Assumes ArriVent BioPharma at Buy, Announces Price Target of $42

Benzinga·03/12/2026 10:52:14
Listen to the news
BTIG analyst Jeet Mukherjee assumes ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Target of $42.